Premium
Autologous cytomegalovirus‐specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia
Author(s) -
Kater Ar P.,
Remmerswaal Ester B. M.,
Nolte Martijn A.,
Eldering Eric,
Van Oers Marinus H. J.,
Van Lier René A. W.
Publication year - 2004
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2004.05070.x
Subject(s) - cytotoxic t cell , ex vivo , immunotherapy , interleukin 21 , cd8 , immunology , t cell , biology , cancer research , immune system , in vivo , in vitro , biochemistry , microbiology and biotechnology
Summary B‐cell chronic lymphocytic leukaemia (B‐CLL) cells express low levels of co‐stimulatory molecules and therefore fail to induce activation and differentiation of tumour‐specific T cells. We have shown that patients with B‐CLL have considerably expanded numbers of cytomegalovirus (CMV) reactive CD8 + T cells. This study demonstrated that B‐CLL cells loaded with CMV peptide not only promoted the ex vivo expansion of autologous, in vivo ‐generated virus‐specific T cells, but also constituted excellent target cells for these cytotoxic Tcells, even without ex vivo re‐stimulation. Directing virus‐specific T cells to B‐CLL may overcome the inadequate immunostimulatory capacity of these cells, which could be exploited for T‐cell mediated immunotherapy.